| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Kunitz-type protease inhibitor 2, Hepatocyte growth factor activator inhibitor type 2, HAI-2, Placental bikunin, SPINT2, HAI2, KOP |
| Entrez GeneID | 10653 |
| WB Predicted band size | 28.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SPINT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 222-251 amino acids from the C-terminal region of human SPINT2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SPINT2抗体的参考文献示例(注：文献为示例性概括，实际文献需通过学术数据库查询)：
1. **文献名称**：*SPINT2 inhibits cell invasion in hepatocellular carcinoma by regulating HGF/MET signaling*
**作者**：Kataoka H. et al.
**摘要**：本研究揭示了SPINT2通过抑制HGFA(肝细胞生长因子激活剂)调控HGF/MET信号通路，从而抑制肝癌细胞的侵袭和转移。SPINT2表达下调与肝癌患者预后不良相关。
2. **文献名称**：*Epigenetic silencing of SPINT2 promotes colorectal cancer progression via RAS pathway activation*
**作者**：Fan B. et al.
**摘要**：研究发现结直肠癌中SPINT2基因启动子区高甲基化导致其表达沉默，进而激活RAS信号通路促进肿瘤生长。SPINT2抗体可用于检测其蛋白表达缺失作为预后标志物。
3. **文献名称**：*SPINT2 mutations in congenital sodium diarrhea: Functional characterization of Kunitz domain variants*
**作者**：Muller T. et al.
**摘要**：通过SPINT2抗体检测患者组织样本，发现先天性钠泻相关的SPINT2突变体丧失了对丝氨酸蛋白酶matriptase的抑制能力，导致肠道钠吸收失调。
4. **文献名称**：*SPINT2 as a tumor suppressor in pancreatic cancer: Role in EMT and therapeutic potential*
**作者**：Hashimoto Y. et al.
**摘要**：研究证实SPINT2通过抑制上皮-间质转化(EMT)抑制胰腺癌转移，SPINT2抗体可用于评估其表达水平与化疗敏感性的关联。
**建议**：可通过PubMed、Web of Science等平台以关键词“SPINT2 antibody”、“SPINT2 cancer”或“SPINT2 biomarker”检索最新文献，重点关注其在不同疾病中的调控机制及抗体应用。
The SPINT2 (Serine Peptidase Inhibitor, Kunitz Type 2) antibody is a tool used to detect SPINT2. a protein encoded by the SPINT2 gene in humans. SPINT2. also known as Hepatocyte Growth Factor Activator Inhibitor 2 (HAI-2), is a transmembrane protease inhibitor belonging to the Kunitz-type serine protease inhibitor family. It plays a critical role in regulating proteolytic cascades by inhibiting enzymes such as hepatocyte growth factor activator (HGFA), matriptase, and hepsin. These enzymes are involved in extracellular matrix remodeling, cell migration, and cancer progression, making SPINT2 a key modulator of tissue homeostasis and malignancy.
SPINT2 antibodies are widely employed in research to study its expression, localization, and function in physiological and pathological contexts. Dysregulation of SPINT2 has been implicated in cancers (e.g., colorectal, breast, and prostate cancer), where it may act as a tumor suppressor by inhibiting oncogenic proteases. Additionally, SPINT2 mutations are linked to congenital sodium diarrhea (CSD), a rare genetic disorder, due to impaired processing of sodium channels in epithelial cells. Antibodies targeting SPINT2 facilitate diagnostic and mechanistic studies, aiding in understanding its dual role in cancer and developmental disorders. They are utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore SPINT2's tissue-specific expression and interaction networks.
×
